Responses
Abstracts Accepted for Publication
Scleroderma, myositis and related syndromes
AB0629 Design of A Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Trial of The Toll-like Receptor Antagonist IMO-8400 in Patients with Dermatomyositis
Compose a Response to This Article
Other responses
No responses have been published for this article.